PHARMACEUTICAL TECHNOLOGY


Introduction
Size reduction is a fundamental unit operation having important applications in pharmacy. It helps in improving solubility and bioavailability, reducing toxicity, enhancing release and providing better formulation opportunities for drugs. In most of the cases, size reduction is limited to micron size range, for example, various pharmaceutical dosage forms like powder, emulsion, suspension etc. Drugs in the nanometer size ....etc

[:=Read Full Message Here=:]

The Indian Pharmaceutical Industry

Letters of Introduction
© 2006 KPMG International. KPMG International is a Swiss cooperative that serves as a coordinating entity for a network
of independent firms operating under the KPMG name. KPMG International provides no services to clients. Each member
firm of KPMG International is a legally distinct and separate entity and each describes itself as such. All rights reserved.
3 Collaboration for Growth
India's entrepreneurial pharmaceutical manufacturers are now beginning to levera ....etc

[:=Read Full Message Here=:]

please help me in getting pharmaceutical hazards ppt. that is very useful for me ....etc

[:=Read Full Message Here=:]

ABSTRACT
The trend among pharmaceutical companies to develop selective drugs of high potency
has pushed the industry to consider the potential of each hazardous ingredient to become
airborne.Dustiness issues are not unique to the pharmaceutical industry, but are relevant
to any industry where powdered materials are mixed, transferred and handled. Interest in
dustiness is also driven by concerns for worker health, the potential for plant explosions
and the prevention of product loss. Unlike other industries, the ....etc

[:=Read Full Message Here=:]

Role of packaging material on Pharmaceutical product stability
What is packaging ?
Packaging is defined as the collection
of different components which surround
the pharmaceutical product from the time
of production until its use
Importance of packaging
• Protect against all adverse external influences
that can alter the properties of the product.
• Protect against biological contamination.
• Protect against physical damage.
• Carry the correct information and identification
of the product.
• Tamper evident / Child ....etc

[:=Read Full Message Here=:]

WEB PHARMACEUTICAL



INTRODUCTION:

This is about management system where full detail about medicine and medical store will be available. There are various type of facilities available in this system as retail booking and finance hospitality and health care etc. One can book medicine from anywhere, can get information regarding medicine and availability. It is most natural interface between people(user) and technology .For medicine booking customer have to fil ....etc

[:=Read Full Message Here=:]

RegentAtlantic Capital, LLC
Michael Steiner is a Wealth Manager and Principal with RegentAtlantic Capital, LLC, and
head of the fi rm’s Pharmaceutical Executive Services Group (PESG). David H. Bugen is a
Wealth Manager and Principal, and Brian Kazanchy is a Wealth Manager. William T. Knox IV
is a Wealth Manager and Principal. Margaret V. Prentice is the Chief Marketing Offi cer and
Principal, and Lauren S. Goldfarb is the Business Development Coordinator.
Fiduciary Network, LLC
Mark P. Hurley is President and CEO of Fiduc ....etc

[:=Read Full Message Here=:]

fundamental analysis of pharmaceutical company ....etc

[:=Read Full Message Here=:]

Project Title: Development of a comprehensive Clinical Trials Management System (CTMS) for a pharmaceutical research organization
Background
Clinical trials are done to see if a new drug or device is safe and effective for people to use. Clinical trials are also done for other reasons such as comparing existing treatments to determine the better one. The current, approved treatments are called the standard treatments. Sometimes clinical trials are used to study different ways to use the standard treatments so they will ....etc

[:=Read Full Message Here=:]

Organometallic Complexes
organometallic is the compounds which are having at least one direct metal-carbon bond. The metal can be main group, transition or f-group metal, also include boron, silicon, germanium, arsenic, antimony, selenium, and tellurium. The carbon-containing group(s) may be a carbonyl, alkyl, alkene, alkyne, aromatic, cyclic, or heterocyclic compound.
* The field of organometallic Pharmaceuticals dates back to the end of the 1970, Kopf and Kopf-Maier investigated the antitumor activity of early tr ....etc

[:=Read Full Message Here=:]